Our well-designed and well-equipped R&D labs and manufacturing facility offer unique and differentiated capabilities ensuring quality and flexibility.

Established in 1999, the company operates out of its corporate headquarters in Thane. The 38,000 square feet office also houses the India R&D center. The R&D center has three formulation facilities. To know more visit our R&D page.

Our R&D center in Ontario, Canada is housed in a 13,609.69 square feet facility with laboratories built to cGMP standards and analytical and characterization capabilities for nasal and inhalation products. It was inspected by the US FDA in July 2016, October 2018, and most recently in November 2023 pursuant to which we received an EIR in December 2023. To know more visit our R&D page.

Our manufacturing facility in Ambernath, Maharashtra, India is 14,250m2 for manufacturing of oral solid dosages and more recently, for manufacturing of unit-dose, bi-dose, and multi-dose nasal sprays. The facility is US FDA approved. The EIR for our Ambernath oral solids facility was issued by the US FDA within 45 days of inspection in January 2023 and our new facility for nasal sprays, also at Ambernath received an EIR in May 2024 after it was inspected by the US FDA for the first time in March 2024.

Our other manufacturing facility in Satara, Maharashtra, India is 4,050 m2 for manufacturing of oral liquid dosages. To know more visit our Manufacturing page.

“We intend to continue to seek additional opportunities that enable us to leverage our research and development to bring innovative products to market with commercial models that we believe can deliver substantial growth and profitability. We intend to opportunistically pursue opportunities to expand our manufacturing capabilities with acquisitions of facilities in India with existing regulatory approvals and capabilities that are complementary to our 225 product portfolio and products under development.”